BCMA/TNFRSF17 蛋白, Human

B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells^[1]. BCMA/TNFRSF17 Protein, Human is a recombinant protein consisting of 50 amino acids (A5-A54) and is produced in E. coli cells.

BCMA 优先由成熟 B 淋巴细胞表达，在造血干细胞或非造血组织中表达最少^[1]。BCMA 几乎只在浆母细胞和 PC 上表达^[2]。
人 BCMA 蛋白的氨基酸序列与小鼠 BCMA 蛋白同源性较低。
BCMA 是一个 184 个氨基酸20.2-kDa III 型跨膜糖蛋白，其胞外 N 末端含有 6 个半胱氨酸的保守基序。BCMA 有两种激动剂配体：增殖诱导配体 (APRIL) 和 B 细胞激活因子 (BAFF)。配体与 BCMA 结合后，激活 B 细胞 (NF-κβ)、大鼠肉瘤/丝裂原激活蛋白激酶 (RAS/MAPK) 和磷酸肌醇 3 激酶蛋白激酶 B/Akt (PI3K-PKB/Akt)信号通路。这些途径通过调节细胞周期检查点来刺激增殖，通过上调抗凋亡蛋白来提高存活率，并产生细胞粘附分子、血管生成因子和免疫抑制分子^[2]。
BCMA可作为一种有前途的抗原，针对 MM 患者使用多种免疫疗法（包括 CART 细胞）进行靶向治疗^[3]。BCMA 显着降低小鼠血浆 IgA、IgG 和 IgM 水平以及脾脏 Ig 重链 mRNA 水平^[4]。在 BCMA−/− 小鼠中，PC 的长期存活受到损害，但缺乏 BCMA 对短寿命的 PC、B 细胞发育或早期体液免疫反应没有影响，并且脾结构和生发中心在这些 BCMA 缺陷小鼠^[5]。BCMA 过表达可显着促进小鼠模型中异种移植 MM 细胞的体内生长^[6]。

BCMA (human; 10000 ng/mL; 24 h) blocks the activity of ARI2m cells and inhibits the IFNγ production^[3].

BCMA (human; 100 µg; i.p.; on days -4, -2, 0, 2, and 4) decreases the IgA and IgM levels in C57 Bl/6 mice^[4].

The ED₅₀ is <40 ng/mL as measured by murine B cells, corresponding to a specific activity of >2.5 × 10⁴ units/mg.

Human

E. coli

Tag Free

Q02223 (A5-A54)

608  [NCBI]

AGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA

Approximately 5.4 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized after extensive dialysis against 30% acetonitrile, 0.1% TFA.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Nobari ST, et al. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med. 2022 Feb 10;20(1):82.  [Content Brief]

  [2]. Hatzoglou A, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 2000 Aug 1;165(3):1322-30.  [Content Brief]

  [3]. Yu B, et al. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125.  [Content Brief]

  [4]. Tai YT, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 Jun 23;127(25):3225-36.  [Content Brief]

  [5]. Perez-Amill L, et al. Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica. 2021 Jan 1;106(1):173-184.  [Content Brief]

  [6]. Sanchez E, et al. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clin Cancer Res. 2016 Jul 1;22(13):3383-97.  [Content Brief]

  [7]. O'Connor BP, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 Jan 5;199(1):91-8.  [Content Brief]

  [8]. Tai YT, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 Jun 23;127(25):3225-36.  [Content Brief]